BR0013719A - Dosagem oral de liberaçâo controlada, apropriada para administração oral - Google Patents

Dosagem oral de liberaçâo controlada, apropriada para administração oral

Info

Publication number
BR0013719A
BR0013719A BR0013719-7A BR0013719A BR0013719A BR 0013719 A BR0013719 A BR 0013719A BR 0013719 A BR0013719 A BR 0013719A BR 0013719 A BR0013719 A BR 0013719A
Authority
BR
Brazil
Prior art keywords
controlled
oral administration
oral
release
oral dosage
Prior art date
Application number
BR0013719-7A
Other languages
English (en)
Inventor
Nirmal Mulye
Original Assignee
Nostrum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nostrum Pharmaceuticals Inc filed Critical Nostrum Pharmaceuticals Inc
Publication of BR0013719A publication Critical patent/BR0013719A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"DOSAGEM ORAL DE LIBERAçãO CONTROLADA, APROPRIADA PARA ADMINISTRAçãO ORAL". A presente invenção se refere a uma composição farmacêutica, preferivelmente na forma de um comprimido compreendendo uma quantidade terapeuticamente eficaz de um medicamento em um veículo compreendendo um polímero insolúvel em água e um sal inorgânico, insolúvel em água.
BR0013719-7A 1999-09-02 2000-08-30 Dosagem oral de liberaçâo controlada, apropriada para administração oral BR0013719A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15211499P 1999-09-02 1999-09-02
PCT/US2000/040781 WO2001015665A1 (en) 1999-09-02 2000-08-30 Controlled release oral dosage suitable for oral administration

Publications (1)

Publication Number Publication Date
BR0013719A true BR0013719A (pt) 2002-07-23

Family

ID=22541568

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0013719-7A BR0013719A (pt) 1999-09-02 2000-08-30 Dosagem oral de liberaçâo controlada, apropriada para administração oral

Country Status (8)

Country Link
US (1) US6437000B1 (pt)
EP (1) EP1207852A4 (pt)
JP (1) JP2003508420A (pt)
AU (1) AU783656B2 (pt)
BR (1) BR0013719A (pt)
CA (1) CA2383212C (pt)
NZ (1) NZ517466A (pt)
WO (1) WO2001015665A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020187192A1 (en) * 2001-04-30 2002-12-12 Yatindra Joshi Pharmaceutical composition which reduces or eliminates drug abuse potential
CN100379408C (zh) * 2003-07-28 2008-04-09 马林克罗特公司 改进的硬脂酸盐组合物及制备方法
US8709476B2 (en) 2003-11-04 2014-04-29 Supernus Pharmaceuticals, Inc. Compositions of quaternary ammonium compounds containing bioavailability enhancers
WO2005046655A1 (en) * 2003-11-04 2005-05-26 Shire Laboratories, Inc. Sustained release of positively charged pharmacologically active molecules from a matrix containing polymers with polarized oxygen atoms
DE602004030931D1 (pt) 2003-11-04 2011-02-17 Supernus Pharmaceuticals Inc
EP1931315B1 (en) 2005-08-24 2013-10-16 Penwest Pharmaceuticals Co. Sustained release formulations of nalbuphine
US8394812B2 (en) 2005-08-24 2013-03-12 Penwest Pharmaceuticals Co. Sustained release formulations of nalbuphine
FR2894143B1 (fr) * 2005-12-01 2008-05-02 Pierre Fabre Medicament Sa Composition a liberation prolongee de l'actif, son procede de preparation et son utilisation.
BRPI0621321A2 (pt) * 2006-02-10 2011-12-06 Mannatech Inc formulações de suplemento dietético de multivitamìnico e multimineral natural para melhor absorção e utilização biológica
US7731604B2 (en) * 2006-10-31 2010-06-08 Taylor Made Golf Company, Inc. Golf club iron head
EP2591675A1 (en) 2006-11-27 2013-05-15 H. Lundbeck A/S Heteroaryl amide derivatives
PL2268160T3 (pl) * 2008-03-20 2013-05-31 Virun Inc Emulsje zawierające pochodną PEG tokoferolu
BRPI0909185A2 (pt) 2008-03-20 2015-08-25 Virun Inc Derivado de vitamina e e seus usos
US8343524B2 (en) * 2008-07-31 2013-01-01 Clarke Mosquito Control Products, Inc. Extended release tablet and method for making and using same
CA2792330C (en) * 2010-03-23 2017-01-03 Virun, Inc Nanoemulsion including a peg-derivative of vitamin e and a sucrose fatty acid ester
IL266008B (en) * 2016-10-17 2022-08-01 Lidds Ab A new method for producing calcium sulphate hemihydrate with unique properties
WO2018127594A1 (en) 2017-01-06 2018-07-12 Oystershell Nv Oral dosage form for enhanced solubilization of a poorly soluble active agent and method of preparation
EP3345591A1 (en) 2017-01-06 2018-07-11 Oystershell NV Oral dosage form for enhanced solubilization of a poorly soluble active agent and method of preparation

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3488418A (en) 1965-11-18 1970-01-06 Sterling Drug Inc Sustained relief analgesic composition
US3584114A (en) 1968-05-22 1971-06-08 Hoffmann La Roche Free-flowing powders
US3773920A (en) 1971-07-14 1973-11-20 Nikken Chemicals Co Ltd Sustained release medicinal composition
US4025613A (en) 1971-07-19 1977-05-24 Richard G. Powers Timed-release aspirin
BE787973A (fr) * 1971-09-04 1973-02-26 Beecham Group Ltd Comprimes pharmaceutiques a effet retard
US4218433A (en) 1977-03-03 1980-08-19 Nippon Kayaku Kabushiki Kaisha Constant-rate eluting tablet and method of producing same
US4361545A (en) 1979-05-21 1982-11-30 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion
US4415547A (en) 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
HU187215B (en) 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
US4690824A (en) 1983-07-07 1987-09-01 Redi-Rowell, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range
US4539198A (en) 1983-07-07 1985-09-03 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range
JPS6124516A (ja) 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd 持続性錠剤
DE3431861A1 (de) 1984-08-30 1986-03-13 Troponwerke GmbH & Co KG, 5000 Köln Pellet-zubereitung
DE3438291A1 (de) * 1984-10-19 1986-04-24 Röhm GmbH, 6100 Darmstadt Verfahren zur herstellung einer waessrigen ueberzugsmitteldispersion und ihre verwendung zum ueberziehen von arzneimitteln
GB8507779D0 (en) 1985-03-26 1985-05-01 Fujisawa Pharmaceutical Co Drug carrier
IE63321B1 (en) 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
GB2186485B (en) 1986-02-13 1988-09-07 Ethical Pharma Ltd Slow release formulation
JPS62223112A (ja) 1986-03-25 1987-10-01 Rooto Seiyaku Kk 歯周病治療剤
US4832957A (en) 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
DE3775880D1 (pt) 1986-09-18 1992-02-20 London School Of Pharmacy Innovations Ltd., London, Gb
US4760094A (en) 1986-10-21 1988-07-26 American Home Products Corporation (Del.) Spray dried acetaminophen
US4767789A (en) 1986-10-21 1988-08-30 American Home Products Corporation (Del.) Spray dried acetaminophen
US4990335A (en) 1987-03-25 1991-02-05 E. I. Du Pont De Nemours And Company Use of vinyl alcohol homopolymer and copolymers for tableting active materials
US5719197A (en) 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5271946A (en) 1988-04-20 1993-12-21 Asta Pharma Aktiengesellschaft Controlled release azelastine-containing pharmaceutical compositions
US5009897A (en) 1988-06-24 1991-04-23 Abbott Laboratories Pharmaceutical granules and tablets made therefrom
JP2514078B2 (ja) 1988-08-22 1996-07-10 エスエス製薬株式会社 圧縮成型製剤
US5002774A (en) 1989-06-08 1991-03-26 Erbamont, Inc. Sustained release pharmaceutical tablet
US4983399A (en) 1989-10-18 1991-01-08 Eastman Kodak Company Direct compression carrier composition
JP2572673B2 (ja) 1990-07-25 1997-01-16 エスエス製薬株式会社 徐放性錠剤
CA2061520C (en) 1991-03-27 2003-04-22 Lawrence J. Daher Delivery system for enhanced onset and increased potency
ATE186544T1 (de) 1992-08-04 1999-11-15 James M Dunn Pharmazeutische formulierungen mit kontrollierter freigabe von 3'-azido-3'-deoxythymidin und verfahren zur verwendung
ZA936723B (en) * 1992-09-14 1995-08-14 Vesta Med Pty Ltd Pharmaceutical preparations for lowering homocysteine levels
TW272942B (pt) 1993-02-10 1996-03-21 Takeda Pharm Industry Co Ltd
HUT77530A (hu) * 1994-05-06 1998-05-28 Pfizer Inc. Azitromicint tartalmazó, szabályozott hatóanyag-felszabadítású dózisformák
DE69633018T2 (de) * 1995-11-14 2004-12-09 Abbott Gmbh & Co. Kg Schilddrüsenhormone enthaltende stabilisierte arzneimittel und verfahren
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives

Also Published As

Publication number Publication date
AU783656B2 (en) 2005-11-24
CA2383212A1 (en) 2001-03-08
JP2003508420A (ja) 2003-03-04
WO2001015665A1 (en) 2001-03-08
EP1207852A4 (en) 2009-11-11
EP1207852A1 (en) 2002-05-29
US6437000B1 (en) 2002-08-20
NZ517466A (en) 2003-11-28
AU1105901A (en) 2001-03-26
CA2383212C (en) 2008-11-25

Similar Documents

Publication Publication Date Title
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
DE60032749D1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
BRPI0518266A2 (pt) medicamento oral de libertaÇço modificada de pelo menos um princÍpio ativo sob a forma multimicrocapsular
CO5190672A1 (es) Composicion para la dosificacion oral, de disolucion instantanea
AR028299A1 (es) Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
BR0014383A (pt) Composições de liberação controlada compreendendo nimesulida
BR9812001A (pt) Composição farmacêutica para combinação de descongestionante piperidinoalcanol
IL139229A0 (en) Drug delivery system comprising a tightly compacted solid medicament stock
BR122012014331A8 (pt) Formulações farmacêuticas
BR0015284A (pt) Formulações de hidrocodona de liberação controlada
ATE213629T1 (de) Milnacipranhaltige darreichungsform mit verzögerter wirkstoffabgabe
PT785775E (pt) Formulacoes opioides extrudidas por fusao administraveis oralmente
AP2003002763A0 (en) Controlled release formulations for oral administration
MX2007015480A (es) Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada.
HUP0004966A3 (en) Pharmaceutical composition for oral administration in the form of matrix tablet enabling the prolonged release of trimetazidine
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
BRPI0412364A (pt) composição farmacêutica sólida, compreendendo amisulpride
BR0308305A (pt) Fórmulas dosadas de liberação controlada
WO2006072940A3 (en) Controlled long acting release pharmaceutical preparation for use in the oral cavity
AR022621A1 (es) Composicion farmaceutica que contiene desoxipeganina para el tratamiento de la dependencia de la nicotina
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
BR0108958A (pt) Sistema de liberação controlada, administrado oralmente, para administração diária de ciprofloxacina
BR0014440A (pt) Formulações de liberação controlada oral
ES2188513T3 (es) Utilizacion de desoxipeganina para el tratamiento de la drogodependencia.
AR039162A1 (es) Formulaciones de venlafaxina de liberacion extendida

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: A61K 9/00

Ipc: A61K 9/22 (2009.01)

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8, 11, 13 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.